Illumina Remains Committed to GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test

SAN DIEGO–(BUSINESS WIRE)–Illumina disagrees with the European Commission’s Directorate-General for Competition’s decision to review Illumina’s acquisition of GRAIL.
Click here to view original post